For Your Adult Patients with Schizophrenia
Why Wait for Another Relapse?
Government Coverage Options
Medicare Low-Income Subsidy (LIS)
Full-benefit, dual-eligible Medicare LIS & Medicaid patients pay
$0 to $10.35 per dose1*
through the Medicare Part D Program
Medicaid fee-for-service patients may pay
less than $8 per dose2†
This information is not a promise of coverage or payment. It is not intended to give reimbursement advice or increase reimbursement by any payer. Legal requirements and plan information can be updated frequently. Contact the plan for more information about current coverage, reimbursement policies, restrictions, or requirements that may apply.
*See full eligibility requirements for the Low-Income Subsidy for Medicare Prescription Drug Coverage: https://www.cms.gov/Medicare/Eligibility-and-Enrollment/LowIncSubMedicarePresCov/EligibilityforLowIncomeSubsidy
†Above 150% of the Federal Poverty Level, patients may pay up to 20% of the amount the Medicaid agency pays. Medicaid Fee-for-Service is a state-specific program. Coverage for INVEGA SUSTENNA® (paliperidone palmitate), INVEGA TRINZA® (paliperidone palmitate), and INVEGA HAFYERA® may depend on the indication as well as other factors. As this information varies by state, it is important to contact the state agency directly or consult its website to obtain product-specific coverage and other information.
Janssen CarePath Savings Program can help eligible patientspay $10 per dose
with an $8,000 maximum program benefit per calendar year or 2 doses, whichever comes first
Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. There is no income requirement. Program does not cover the cost to give patients their injection. See full eligibility requirements at InvegaHafyera.JanssenCarePathSavings.com.
Janssen CarePath Is Your One Source for Access, Affordability, and Treatment Support for Your Patients
Janssen CarePath helps verify insurance coverage for your patients, provides reimbursement information, helps find financial assistance options for eligible patients, and provides ongoing support to help patients start and stay on prescribed INVEGA HAFYERA®.
REFERENCES: 1. Announcement of Calendar Year (CY) 2023 Medicare Advantage (MA) capitation rates and Part C and Part D payment policies. Centers for Medicare & Medicaid Services. April 4, 2022. Accessed January 31, 2023. https://www.cms.gov/files/document/2023-announcement.pdf 2. Cost Sharing and Premiums: Benefits. Medicaid and CHIP Payment and Access Commission. Accessed January 31, 2023. https://www.macpac.gov/subtopic/cost-sharing-and-premiums/